Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 20

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 20
---
,652 Preferred Shares issued and outstanding as of the date hereof, which     
 will automatically convert upon the completion of this offering at a 1:1 ratio; (ii) the issuance of 609,888 Ordinary Shares upon       
 the automatic conversion of the $900,000 outstanding principal of the 2020 CLAs, which will occur upon the completion of this offering; 
 (iii) the issuance of 553,640 Ordinary Shares upon the automatic conversion of the $450,000 outstanding principal of the 2024 CLAs,     
 which will occur upon the completion of this offering; (iv) the receipt of an additional $100,000 under the Bridge Loan subsequent      
 to December 31, 2024; (v) the receipt of a loan in the total amount of $200,000 pursuant to the 2025 Loan Agreements; and (iv) the      
 expiration of certain outstanding warrants to purchase up to 167,365 Ordinary Shares in March 2025.                                     |

| (2) | The Pro Forma As Adjusted data gives additional                                                                                          
 effect to: (i) the sale of  1,000,000 Ordinary Shares in this offering at an initial public offering price of $11.00 per                 
 Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting    
 discounts and commissions and estimated offering expenses payable by us; (ii) repayment of the Bridge Loan in the total amount of        
 $350,000 plus accrued interest and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the loan under the        
 2024 Loan Agreements in the total amount of $150,000 plus accrued interest and an aggregate risk premium in the amount of $50,000;       
 (iv) the repayment of loan under the December 2024 Loan Agreement in the total amount of $117,000 plus accrued interest and an aggregate 
 risk premium of approximately $35,100; and (v) the repayment of the loan under the 2025 Loan Agreements in the total amount of $200,000  
 plus accrued interest and an aggregate risk premium in the amount of $100,000.                                                           |

The as adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. Each $0.25 increase (decrease) in the assumed initial public offering price of $11.00